Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

57
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
57
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

292
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
292
Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

329
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
329

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anhedonia in patients with major depressive disorder (MDD): State-of-the-art consensus review.

Psychiatry research·2026
Same author

The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD<sup>✰</sup>.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Examining recruitment differences by race, ethnicity, and age to a decentralized trial of an internet-delivered intervention for sexual health after breast cancer: the WF-2202 SHINE trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Efficacy and Clinical Relevance of Adjunctive Cariprazine Treatment in Patients with Major Depressive Disorder: Post Hoc Analyses from a Phase III Study.

Neuropsychiatric disease and treatment·2026
Same author

Psychiatric disorders, psychopharmacology and sexual dysfunction from the fifth international consultation on sexual medicine (ICSM 2024).

Sexual medicine reviews·2026
Same author

The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.

The British journal of psychiatry : the journal of mental science·2026
Same journal

The interplay between the obsessive-compulsive disorder and sexual function: a systematic review.

Sexual medicine reviews·2026
Same journal

Ancient South Asian traditions and the cultural foundations of sexual medicine: from kāma to clinical care.

Sexual medicine reviews·2026
Same journal

Postoperative impact of pelvic organ prolapse and urinary incontinence surgeries on female sexual function measured by validated instruments: a systematic review and meta-analysis.

Sexual medicine reviews·2026
Same journal

Efficacy and safety of acupuncture for erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials.

Sexual medicine reviews·2026
Same journal

Mapping the evidence on sexual desire and sexual interest in transgender populations: a scoping review.

Sexual medicine reviews·2026
Same journal

The association between ejaculatory dysfunction and lumbosacral disorders: a systematic review of an underrecognized clinical link.

Sexual medicine reviews·2026
See all related articles

Related Experiment Video

Updated: Feb 25, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.1K

Flibanserin: From Bench to Bedside.

Erin M Dooley1, Melanie K Miller1, Anita H Clayton1

  • 1University of Virginia, Charlottesville, VA, USA.

Sexual Medicine Reviews
|August 1, 2017
PubMed
Summary
This summary is machine-generated.

Flibanserin (Addyi) is the first drug approved for hypoactive sexual desire disorder in women. Its complex FDA approval process involved extensive research on efficacy and safety, overcoming significant challenges.

Keywords:
Female Sexual DysfunctionFlibanserinFood and Drug AdministrationHypoactive Sexual Desire Disorder

More Related Videos

A Benchtop Approach to the Location Specific Blood Brain Barrier Opening using Focused Ultrasound in a Rat Model
08:58

A Benchtop Approach to the Location Specific Blood Brain Barrier Opening using Focused Ultrasound in a Rat Model

Published on: June 13, 2020

5.0K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K

Related Experiment Videos

Last Updated: Feb 25, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.1K
A Benchtop Approach to the Location Specific Blood Brain Barrier Opening using Focused Ultrasound in a Rat Model
08:58

A Benchtop Approach to the Location Specific Blood Brain Barrier Opening using Focused Ultrasound in a Rat Model

Published on: June 13, 2020

5.0K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K

Area of Science:

  • Pharmacology
  • Women's Health
  • Drug Approval Process

Background:

  • Hypoactive sexual desire disorder (HSDD) affects an estimated 10% of women.
  • Flibanserin (Addyi) is the first medication approved for HSDD.
  • The drug's approval was preceded by significant controversy regarding diagnosis validity, safety, and efficacy.

Purpose of the Study:

  • To examine the Food and Drug Administration (FDA) approval process for flibanserin.
  • To review the research, concerns, and obstacles encountered during flibanserin's development and approval.

Main Methods:

  • A literature review was conducted using keywords: flibanserin and hypoactive sexual desire disorder.
  • Included analysis of commentary from proponents and critics of the medication.
  • Focused on the challenges leading to the drug's approval.

Main Results:

  • Flibanserin demonstrated significant improvements in satisfying sexual events, sexual desire, and reduced sexual distress in premenopausal women across three trials.
  • Key safety concerns included sedation, syncope, hypotension, and interactions with alcohol and CYP3A4 inhibitors.
  • The FDA mandated additional targeted challenge studies to assess safety.

Conclusions:

  • Flibanserin's approval was a lengthy process, partly due to it being the first drug in its class.
  • Lack of clear FDA guidance on study design and development pathways contributed to the extended approval timeline.